Antibody-IL-10 fusion proteins
US10975134B2 · kind B2 · utility
18Cited by
1References
10Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Aug 25, 2020 |
| Grant date | Apr 13, 2021 |
| Priority date | — |
| Expiry date | Aug 25, 2040 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The application relates to compositions or formulations comprising variant IL-10 molecules, fusion proteins, and chimeric proteins thereof useful for the treatment of cancer, inflammatory diseases or disorders, and autoimmune diseases or disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.